SOUTH SAN FRANCISCO, Calif. (AP) _ CytomX Therapeutics Inc. (CTMX) on Wednesday reported a loss of $29 million in its second quarter.
The South San Francisco, California-based company said it had a loss of 64 cents per share.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.
The biopharmaceutical company posted revenue of $9 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $15.1 million.
CytomX Therapeutics shares have dropped 28% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $10.92, a decrease of 56% in the last 12 months.